-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：杜邦公司公佈了令人矚目的2026財年第一季業績，調整後每股收益為0.55美元，高於去年同期的0.36美元，超出市場普遍預期的0.48美元。淨銷售額成長4%（高於我們先前3%的預期），其中有機成長2%，營業EBITDA利潤率從22.3%提升230個基點至24.6%。營業現金流從7,700萬美元成長至2.32億美元，增幅超過兩倍；經交易調整後的自由現金流年增800萬美元，達到1.47億美元；營業EBITDA成長15%，達4.14億美元。我們對這些業績表示讚賞，杜邦公司在所有指標上均表現強勁，同時完成了策略性產品組合轉型，展現了其定價能力，在終端市場狀況不一的情況下，仍實現了1%的定價貢獻和顯著的利潤率提升。隨著芳綸資產剝離完成，並已獲得 18 億美元的收益，管理層已做好充分準備，在投資利潤率更高的醫療保健和水技術業務的同時，加快股東回報。
Related Articles
Australia
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
$MPC
Research
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
$PEG
Australia
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%
$MRK$TERN